Spots Global Cancer Trial Database for shr6390
Every month we try and update this database with for shr6390 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | NCT05228951 | Breast Cancer | Pyrotinib malea... | 18 Years - 75 Years | Shengjing Hospital | |
| Study of SHR6390 in Renal Insufficiency and Healthy Subjects | NCT05515289 | Breast Cancer | SHR6390 | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer | NCT03480256 | Gastric Cancer | SHR6390 | 18 Years - 75 Years | Peking University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | NCT04355858 | Breast Cancer Metastatic Canc... | SHR7390 Famitinib SHR3162 Pyrotinib Capecitabine SHR1210 Everolimus Nab paclitaxel SHR2554 SHR3680 SHR6390 SHR1701 SERD AI VEGFi | 18 Years - 75 Years | Fudan University | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | NCT04733417 | Advanced Breast... Metastatic Brea... | SHR6390 famitinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | NCT03927456 | Advanced Breast... | SHR6390 Placebo Fulvestrant | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | NCT04733417 | Advanced Breast... Metastatic Brea... | SHR6390 famitinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | NCT04095390 | Metastatic Brea... HER2-positive B... | Pyrotinib SHR6390 Letrozole Capecitabine | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | NCT03601598 | CRC HCC NSCLC | SHR-1210 SHR6390 | 18 Years - 75 Years | Harbin Medical University | |
| Study of SHR6390 in Renal Insufficiency and Healthy Subjects | NCT05515289 | Breast Cancer | SHR6390 | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | NCT03601598 | CRC HCC NSCLC | SHR-1210 SHR6390 | 18 Years - 75 Years | Harbin Medical University | |
| A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | NCT04095390 | Metastatic Brea... HER2-positive B... | Pyrotinib SHR6390 Letrozole Capecitabine | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| A Study of SHR6390 in Advanced Solid Tumor Patients | NCT02684266 | Neoplasm | SHR6390 | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02 | NCT05205200 | Breast Cancer Metastatic Canc... | SHR-1316 SHR6390 Nab paclitaxel SERD AI | 18 Years - 75 Years | Fudan University | |
| A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | NCT02671513 | Melanoma | SHR6390 | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
